MedTrace Logo

GLEAM: Noninvasive Glucose Measurement Using Impedance Tomography

NCT06223204 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2024-05-02

No results posted yet for this study

Summary

The GLEAM study aims at assessing the potential of electrical impedance tomography (EIT) for noninvasive glucose measurement.

Conditions

Interventions

OTHER

Controlled euglycemia, hypoglycemia and hyperglycemia

EIT measurements are collected in different glycemic states (euglycemia, hypoglycemia and hyperglycemia). Venous blood glucose is measured using a gold-standard glucose analyzer.

Sponsors & Collaborators

  • CSEM Centre Suisse d'Electronique et de Microtechnique SA

    collaborator UNKNOWN

  • Idiap Research Institute

    collaborator UNKNOWN

  • Insel Gruppe AG, University Hospital Bern

    lead OTHER

Principal Investigators

  • Christoph Stettler, Prof. MD · Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism; Bern, Switzerland

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-31
Primary Completion
2024-04-10
Completion
2024-04-10

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06223204 on ClinicalTrials.gov